Article Text

Download PDFPDF

Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease
  1. Ian H Gilbert1,
  2. Sumiti Vinayak2,
  3. Boris Striepen3,
  4. Ujjini H Manjunatha4,
  5. Ibrahim A Khalil5,
  6. Wesley C Van Voorhis6
  7. Cryptosporidiosis Therapeutics Advocacy Group CTAG
    1. 1 DDU, University of Dundee, Dundee, UK
    2. 2 Department of Pathobiology, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA
    3. 3 Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA
    4. 4 Global Health, Novartis Institutes for BioMedical Research, Inc, Emeryville, California, USA
    5. 5 Department of Health, State of Washington, Seattle, Washington, USA
    6. 6 Medicine, Div AID, University of Washington, Seattle, Washington, USA
    7. 7 Various Institutions, Various Cities, Various Countries
    1. Correspondence to Wesley C Van Voorhis; wesley{at}

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Early childhood cryptosporidiosis causes acute disease and mortality, as well as lasting malnutrition and developmental delay. However, there are no safe and effective therapeutics for cryptosporidiosis. Developing such therapeutics will save hundreds and thousands of lives in young children and spare millions of disability-adjusted life years lost (DALYs). This white paper discusses the global public health impact of Cryptosporidium infections, the immediate need for more effective treatment of cryptosporidiosis, and recent advances that are yielding multiple promising leads for therapeutic development. We will discuss the remaining challenges, which is to complete the preclinical and clinical steps to bring these novel therapeutics to children in urgent need of treatment.

    Diarrhoeal diseases cause unacceptable loss of life, mainly among infants and children in low-income and middle-income countries (LMICs). The Global Enteric Multicentre Study (GEMS) revealed the pathogens associated with diarrhoea in children in LMICs.1 Of particular prevalence, as cause of severe disease, were rotavirus, Cryptosporidium spp, enterotoxigenic Escherichia coli and Shigella. The parasite Cryptosporidium (C. hominis and C. parvum) remains one of the most lethal pathogens for malnourished infants and children, with a devastating health impact on those under 2 years of age. The GEMS study estimated about 7.5 million cases of Cryptosporidium infection occur every year within this population in Africa and Asia resulting in over 200 000 Cryptosporidium-attributable deaths due to moderate-to-severe diarrhoea, with an excess of 59 000 deaths compared with children with similar symptoms that were Cryptosporidium negative.2

    Cryptosporidium infection in these malnourished children is also significantly associated with debilitating stunted growth contributing to excess mortality.3–6 This Cryptosporidium-associated stunting and wasting leads to poor physical and neurological health with poor childhood development, resulting in a lasting effect on population health in LMICs.5 This burden falls disproportionately on children in sub-Saharan Africa, but also in South America and Asia (figure 1). In 2018, Dr Khalil and coworkers at the Institute for Health Metrics and Evaluation reported that acute Cryptosporidium infection was associated with an annual loss of greater than 4.2 million DALYs.3 Each DALY represents the loss of a full year of healthy life. In 2019, the Global Burden of Disease study revised the number of deaths and DALYs attributable to Cryptosporidium to 133 422 deaths and 8.2 million DALYs per year, taking into account both the acute and long-term effects of Cryptosporidium infection.7 To put this in perspective with other diarrhoeal diseases within the same 2019 study, cholera is attributable to less deaths (117 000) and DALYs (7.1 million), and both Shigella and Rotavirus were responsible for only slightly more deaths (148 000 and 235 000, respectively) and DALYs (10 million and 17 million).7 In contrast to cryptosporidiosis, vaccines or treatments are available or in advanced development for these infections. Notably, when comparing Cryptosporidium with WHO recognised neglected tropical diseases (NTDs), it greatly exceeds both the deaths and DALYs associated with essentially all of these diseases (figure 2).8

    Figure 1

    Total (acute and long-term) Cryptosporidium DALYs per 1000 child-years among children under 5 (GBD estimates and geographic distribution, Ibrahim Khalil). DALYs after accounting for undernutrition-associated DALYs due to cryptosporidiosis.7 DALYs, disability-adjusted life years lost; GBD, Global Burden of Disease.

    Figure 2

    Infectious disease deaths and DALYs by WHO region.8 There are estimated to be 133 000 deaths per year and 8200K DALYs due to cryptosporidiosis (pink), which greatly exceed the WHO NTDs, note differences in scales. DALYs, disability-adjusted life years lost; NTDs, neglected tropical diseases.

    Effective treatment to mitigate the impact of cryptosporidiosis on child health and survival is woefully lacking. Nitazoxanide is the only US Food and Drug Administration (FDA) approved therapeutic for treating Cryptosporidium infection. It has been shown to be ineffective in immunocompromised individuals and less than 50% effective in malnourished children less than 5 years old.9 Nitazoxanide in vitro does have direct activity against Cryptosporidium, but only at concentrations much higher than those achieved during therapy. Animal models suggest nitazoxanide likely relies on stimulation of the immune system to expel Cryptosporidium. Those most threatened by infection, malnourished children and the immunocompromised cannot mount the immune response required for effective therapy with nitazoxanide.10 11

    This unmet medical need inspired a recent surge in Cryptosporidium research that has yielded the modern experimental tools and facile animal models needed to discover antiparasitic compounds and validate their targets.12–23 Most importantly, safe and effective compounds in preclinical models with direct action against Cryptosporidium have emerged.13 15 16 18 24–31 This represents a major advance, significantly expanding the quality and quantity of the portfolio. Multiple drug candidates are now progressing towards preclinical development and clinical trials at an uneven pace (table 1). The initial high-risk research that led to these compounds was conducted by multiple academic and industry groups, often with extensive academic and industry collaboration and with governmental and philanthropic support. Now further investments are needed to capitalise on this rich portfolio and accelerate the development and registration of transformative therapies for this largely unmet medical need.

    Table 1

    Examples of compounds in preclinical development

    A vaccine that prevents Cryptosporidium morbidity and mortality would be of great benefit to childhood health in LMICs, and research towards vaccination should be supported. However, natural immunity to Cryptosporidium is non-sterile and requires multiple infections, highlighting the parasite’s potential to evade immunity. Developing vaccines to address parasitic infections, like Cryptosporidium, has been difficult and we are probably at least a decade from having a safe and effective vaccine. Developing a therapeutic will allow us to address child health in LMICs in a much faster time frame. Even after vaccines arrive, there will be a need for drugs because of insufficient protection, lack of coverage and challenges of roll-out and delivery.

    Multiple recent efforts centred in academia, industry and in joint venture have produced highly promising late preclinical therapeutic leads that are markedly superior to nitazoxanide in preclinical models (table 1). This is a truly transformative advance in both quality and quantity offering a viable path towards treatment. These compounds now require varying degrees of advanced preclinical testing, and clinical trials performed before they can be deployed. The target population is infants, however, for a proof of concept (phase 2a) study, testing in infants is inadvisable due to safety, pharmacokinetic and ethical challenges. Cryptosporidiosis is typically rare in adults living in high transmission areas due to acquired immunity, except in HIV/AIDS patients. Recent advances in the clinical evaluation of novel antimalarials provide critical guidance forward. Human challenge models using healthy volunteers have proven an invaluable tool32 33 providing an insight into efficacy without the risks associated with highly vulnerable populations. Multiple such studies have been conducted with Cryptosporidium in the past and were found to be safe34–36 and the model has recently be updated.37 We support a clinical trial plan proposed in which the proof of concept (phase 2a study) is conducted with volunteers intentionally infected with C. parvum, followed by phase 2b and 3 studies in children in endemic areas.37

    Since malaria and Cryptosporidium belong to the same phylum Apicomplexa, they share some conserved drug targets, and thus there is a synergy possibility in research and development of malaria and Cryptosporidium therapeutics. But like malaria, Cryptosporidium may develop resistance to monotherapy, given the high numbers of parasites during infection. Indeed, emergence of resistance has been documented in the newborn calf model of infection for one compound that targets methionyl-tRNA-synthetase.38 Therefore, it is probably necessary to take several compounds through clinical development to provide the possibility of combination treatment (table 1). There are also possibilities for synergy with the animal health market, particularly for dairy cattle, where in some areas nearly 100% of newborn calves acquire C. parvum infection, and Cryptosporidium infection has been shown to lead to lasting weight loss and reduced milk production.39–41

    A challenge to be addressed is the clinical usage of an anti-Cryptosporidium drug. Studies indicate that there are multiple causes of diarrhoea; as indicated above, causative organisms include Shigella spp, enterotoxigenic E. coli, Campylobacter jejuni and rotavirus. There is current compelling evidence of unmet therapeutic need for enteric cryptosporidiosis found in three patient groups: (1) young children aged 0–24 months in LMICs; (2) malnourished children under age 5 and (3) immunosuppressed individuals of any age.42 43 A recent publication outlines an effective therapeutic could be used to reduce the large burden of Cryptosporidium in LMICs (table 2).42 Cryptosporidium therapy could be used syndromically, for instance in children less than 2 years old with moderate-to-severe diarrhoea, probably combined with an antibacterial to cover the major treatable causes, E. coli, Shigella spp. and C. jejuni. Treatment could be carried out with a diagnostic, such as a point-of care rapid antigen detection test, or a PCR, similar to that used in SARS-CoV-2 detection. This diagnostic-directed therapy might be especially helpful in malnourished children less than 5 years old, where asymptomatic and mildly symptomatic Cryptosporidium has been shown to be highly associated with poor outcomes, such as stunting, poor physical and mental development and excess deaths from other causes. These diagnostic tools are available now, and the rapid antigen detection test can be done at small village clinics where sick and malnourished children are first seen. In the event that a compound or combination with appropriate safety profile can be developed, mass drug administration could be used, particularly given the high infectivity of the parasite and the fact that many infants are likely to be chronically infected.

    Table 2

    Use case scenarios for an anti-Cryptosporidium therapeutic for LMICs adapted from 42

    Beyond this, the authors believe that Cryptosporidium should be formally recognised as a NTD by the WHO, for its major impact is in LMICs and predominantly affects infants and young children. As noted above, Cryptosporidium has a very significant impact compared with many other NTDs currently listed by the WHO (figure 2). This status will bring the critical medical need of Cryptosporidium treatment to the attention of funding bodies, foundations, international health organisations and pharmaceutical companies. Cryptosporidium should also be on the list of tropical infections eligible for a priority review voucher (PRV) by US FDA.44 The PRV programme has proven to be an important financial incentive to pharmaceutical companies wishing to develop drugs for NTDs.

    There are some exciting compounds at a later preclinical or early clinical stage. This calls for more funding to move these leads into clinical trials, to properly evaluate the effect that they will have on millions of people (primarily infants and young children). Going into the clinic will enable us to determine the profile of a drug that can have clinical impact and to establish a way for its use.

    Thus, in summary, using either deaths or DALYs as parameters, the unmet medical need for Cryptosporidium infection exceeds that of most NTDs and causes a huge impact on Africa and Asia. The current therapeutic available is inadequate for the vast majority of this unmet medical need. Tenable use case scenarios exist for how more effective therapeutics for Cryptosporidium infection could be deployed to reduce deaths and DALYs. Cryptosporidium should be recognised as a major unmet medical need and designated a NTD by the WHO and as a tropical disease with PRV status by the US FDA. The fastest way to address the unmet need is to close funding gaps in preclinical candidates and clinical trials, and this should lead to an effective Cryptosporidium therapeutic in a few years.

    Data availability statement

    No data are available.

    Ethics statements

    Patient consent for publication

    Ethics approval

    Not required.



    • Handling editor Seye Abimbola

    • Collaborators Cryptosporidiosis Therapeutics Advocacy Group: Samuel L M Arnold, PhD, University of Washington School of Pharmacy; Beatriz Baragana, PhD, University of Dundee; Lynn Barrett, University of Washington; Frederick S Buckner, MD, University of Washington; Jeremy D Burrows, Phil, Medicines for Malaria Venture; Maria A Caravedo, MD, University of Texas Medical Branch; Ryan Choi University of Washington; Robert K M Choy, PhD, PATH; Eugenio de Hostos, PhD, Calibr at Scripps Research; Thierry Diagana, PhD, Global Health, Novartis Institutes for BioMedical Research, Inc.; Suzanne Duce, PhD, University of Dundee; Rashidul Haque, MB, PhD, ICDDR, B; Matthew A Hulverson, University of Washington; Christopher D Huston, MD, University of Vermont; Pui-Ying D Iroh Tam, DMed, Malawi-Liverpool Wellcome Programme; Paul Kelly, MD, TROPGAN, University of Zambin; Tom Kennedy, PhD, Eleven Bravo LLC; Ibrahim A Khalil, MPH, University of Washington; Minju Kim, University of Washington Hans Rosling Center Global Health; Poonum Korpe, MD, Johns Hopkins Bloomberg School of Public Health; Benoît Laleu, PhD, Medicines for Malaria Venture; Diana Lalika, University of Washington; Fabrice Laurent, PhD, INRAE, Univ. of Tours; Case W McNamara, PhD, Calibr at Scripps Research; Marvin J Meyers, PhD, St. Louis University; Roberta M O’Connor, PhD, University of Minnesota; Kayode K Ojo, PhD, University of Washington; Philipp Olias, PhD, Justus-Liebig-University Giessen; Richard Omore, PhD, Kenya Research Institute, Center for Global Health Research; Nede Ovbiebo, University of Washington; James Platts-Mills, MD, University of Virginia; Mattie C Pawlowic, PhD, University of Dundee; William A Petri, Jr MD, PhD, University of Virginia; Gladys Queen, MS, University of Washington; Divya Rao, University of Washington; Kevin Reed, PhD, University of Dundee; Michael W Riggs, DVM, University of Arizona; Jennifer L Roxas, PhD, University of Arizona; Adam Sateriale, PhD, The Francis Crick Institute; Deborah A Schaefer, MS University of Arizona; L David Sibley, PhD, Washington University in St. Louis; Jonathan M Spector, MPH, Global Health, Novartis Institutes for BioMedical Research, Inc.; Chris Tonkin, PhD, The Walter and Eliza Hall Institute of Medical Research; Timilehin E Toye, BPHARM, University of Washington; Saul Tzipori, DVM, PhD,Ds, Tufts University; Timothy Wells, PhD, Medicines for Malaria Venture; A Clinton White, MD University of Texas,Medical Branch; Grace S Yang, University of Washington.

    • Contributors WCVV made the first draft, modified each draft. IG revised the first draft and led the writing group of the other authors. All the other authors revised the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.